Back to search
FDAFDA · Food and drugs·Recall number D-1164-2016

MIDAZOLAM HCl in 0.9% Sodium Chloride Injection, 2 mg/2 mL (1 mg/mL), in 2 mL syringe, Rx only, Cantrell Drug Co., Little Rock, AR --- NDC 52533-001-16 UPC: 0100352533001161

Published July 13, 2016 · Recall initiated: August 21, 2015

Summary

FDA records drug Class II recall D-1164-2016, published July 13, 2016 and initiated August 21, 2015. Recalling firm: Cantrell Drug Company; Status: Terminated; Reported quantity: 1570 syringes; Lot: Lot: 6178, exp, 9/12/15; 6529, exp 11/22/15. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cantrell Drug Company
Distributor
Nationwide
UPC
01003525330011
Lot
Lot: 6178, exp, 9/12/15; 6529, exp 11/22/15
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was MIDAZOLAM HCl in 0.9% Sodium Chloride Injection, 2 mg/2 mL (1 mg/mL), in 2 mL syringe, Rx only, Cantrell Drug Co., Little Rock, AR --- NDC 52533-001-16 UPC: 0100352533001161 recalled?

Yes. FDA published recall D-1164-2016 on July 13, 2016. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail

How do I know if my unit is part of the recall?

Compare your product details with the notice. UPC: 01003525330011.